Human papillomavirus vaccine recombinant pentavalent - Merck

Drug Profile

Human papillomavirus vaccine recombinant pentavalent - Merck

Alternative Names: 5-valent HPV L1 VLP vaccine - Merck; Human papillomavirus (types 31, 33, 45, 52, 58) L1 virus-like particle vaccine - Merck; Pentavalent HPV VLP vaccine - Merck; Prophylactic 5-valent HPV (Types 31, 33, 45, 52, 58) L1 virus-like particle vaccine - Merck; V-504

Latest Information Update: 25 Feb 2014

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Merck & Co
  • Class Cancer vaccines; Papillomavirus vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Cervical cancer; Human papillomavirus infections

Most Recent Events

  • 01 Oct 2007 Phase-II clinical trials in Cervical cancer (prevention) in USA, Sweden and Austria (IM)
  • 01 Oct 2007 Phase-II clinical trials in Human papillomavirus infections (prevention) in USA, Sweden and Austria (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top